Hospitals across the United States spent approximately $25.4 billion more than necessary this year on supply chain operations, according to a new report from Chicago-based Navigant Consulting. That number is up more than 10 percent compared to 2017.

A novel risk score incorporating patient demographics and clinical characteristics known ahead of hospital discharge can accurately identify CVD patients at low and high risk for 90-day readmission after an initial acute MI (AMI), according to research published in the October edition of Circulation: Cardiovascular Quality and Outcomes.

With strong earnings for the quarter, UnitedHealth Group executives were bullish on the healthcare organization’s growth, and outlined its 2019 plan, including a new health record platform.

The rise of burnout in medicine is well documented, and it is only growing among radiologists, wrote authors of a recent Journal of the American College of Radiology study. The results are particularly concerning in pediatric radiology.

Delaying treatment for stroke patients may significantly increase healthcare and societal costs while shortening quality of life for every hour that goes by, according to a study presented Oct. 18 at the World Stroke Congress in Montreal, Québec, Canada.

An FDA-cleared virtual physical therapy platform is cheaper and just as effective as traditional therapy treatment, according to a recent study.

Breast density notification laws were designed to motivate supplemental breast cancer screening among women at an increased risk. However, they have resulted in more low-risk women undergoing unnecessary supplemental screening, according to new research published in the Journal of the American College of Radiology.

Cardiologists and researchers alike are calling for the early halt of a national heart stem cell trial after Harvard Medical School and Brigham and Women’s Hospital expressed concern earlier this week that some of the work the study is based on might be falsified.

The HeartMate 3 left ventricular assist device (LVAD) has gained FDA approval for advanced heart failure patients ineligible for a transplant, manufacturer Abbott announced Oct. 19.

The savings opportunity for the hospital supply chain has jumped to $25.4 billion per year, meaning some hospitals are leaving millions in savings on the table, according to a recent study from Navigant.